All In MedTech

Device Trial Radar · NCT06556563

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Optune® (TTFields, 200 kHz) Concomitant With Maintenance Temozolomide and Pembrolizumab Versus Optune® Concomitant With Maintenance Temozolomide and Placebo for the Treatment of Newly Diagnosed Glioblastoma (EF-41/KEYNOTE D58).

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 741 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

741

Planned (sponsor's estimate)

Start

Feb 3, 2025

Primary completion

Apr 2029

Study completion Apr 2029

Sponsor

Lead sponsor
NovoCure GmbHNot on our public-company list
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Aug 16, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together with maintenance TMZ and placebo in newly diagnosed Glioblastoma (GBM) patients. The primary objective of the study is to evaluate the Overall Survival (OS).

Conditions

  • Glioblastoma

Interventions

  • Optune® deviceDevice

    Optune® device delivering TTFields therapy at 200 kHz.

  • TemozolomideDrug

    Temozolomide per approved labeling.

  • PembrolizumabDrug

    Pembrolizumab dose throughout this study is 200 mg IV Q3W for a maximum of 35 cycles.

  • PlaceboDrug

    Placebo (saline solution) dose throughout this study is 200 mg IV Q3W for a maximum of 35 cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survivalTime frame: 24 months

Locations

102 sites in 12 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Hospital

    Phoenix, Arizona

  • University of Southern California

    Los Angeles, California

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California

99 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.